Silo Pharma (NASDAQ: SILO) announced that its wholly owned subsidiary, QwikAgents, has been accepted into Advanced Micro Devices' AMD AI Developer Program. The program provides QwikAgents with access to AMD Developer Cloud credits, AI development tools, training resources, and a global developer community. According to the company, this participation is expected to accelerate the development, testing, optimization, and deployment of its AI agent platform across consumer and enterprise applications.
QwikAgents is developing a platform that enables users to deploy persistent AI agents for tasks including research, content generation, scheduling, coding, and workflow automation. Silo stated that participation in the AMD AI Developer Program is expected to support platform performance, agent reliability, and scalable deployment as QwikAgents expands its capabilities for individuals, developers, small businesses, and enterprise customers.
The acceptance into the AMD program marks a strategic step for QwikAgents, which aims to leverage AMD's infrastructure to enhance its AI offerings. By utilizing AMD Developer Cloud credits, QwikAgents can test and optimize its platform on high-performance computing resources, potentially improving the efficiency and speed of its AI agents. The training resources and developer community also provide valuable support for overcoming technical challenges and refining the platform's features.
Silo Pharma, the parent company, is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus includes addressing underserved conditions such as stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio includes programs like SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis, with research conducted in collaboration with leading universities and laboratories.
The integration of QwikAgents into the AMD AI Developer Program underscores the growing convergence of AI and biotech, as Silo Pharma leverages AI-driven tools to potentially streamline operations and enhance research capabilities. While the primary focus of QwikAgents is on general AI agent deployment, the platform could find applications within Silo's biopharmaceutical research, such as automating data analysis or managing complex workflows.
For more information on Silo Pharma, visit silopharma.com. The latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. To view the full press release, visit https://ibn.fm/313SC.
